Lenvima
(Lenvatinib)
(10 mg)
(thirty)
(Таб)
Lenvima (lenvatinib) 10 mg, 30 tablets, Eisai, UK
Article:
In Stock
Thyroid Cancer: Progressive, radioactive iodine-refractory differentiated thyroid cancer.Renal Cell Carcinoma (RCC): First-line with pembrolizumab, or with everolimus after prior anti-angiogenic therapy.Hepatocellular Carcinoma (HCC): First-line treatment for unresectable disease.Endometrial Carcinoma: In combination with pembrolizumab for advanced, non-MSI-H/dMMR cases following prior therapy.
-
Commercial name:Lenvima
-
Сhemical name:Lenvatinib
-
Dosage:10 mg
-
Quantity:thirty
-
Release form:Таб
No reviews yet